| Literature DB >> 32348439 |
Takao Fuchigami1, Hajime Suzuki1, Takuya Yoshimura1, Toshiro Kibe1, Elissa Chairani1, Tohru Kiyono2, Michiko Kishida3, Shosei Kishida3, Norifumi Nakamura1.
Abstract
Objective Ameloblastoma is a representative odontogenic tumor comprising several characteristic invasive forms, and its pathophysiology has not been sufficiently elucidated. A stable animal experimental model using immortalized cell lines is crucial to explain the factors causing differences among the subtypes of ameloblastoma, but this model has not yet been disclosed. In this study, a novel animal experimental model has been established, using immortalized human ameloblastoma-derived cell lines. Methodology Ameloblastoma cells suspended in Matrigel were subcutaneously transplanted into the heads of immunodeficient mice. Two immortalized human ameloblastoma cell lines were used: AM-1 cells derived from the plexiform type and AM-3 cells derived from the follicular type. The tissues were evaluated histologically 30, 60, and 90 days after transplantation. Results Tumor masses formed in all transplanted mice. In addition, the tumors formed in each group transplanted with different ameloblastoma cells were histologically distinct: the tumors in the group transplanted with AM-1 cells were similar to the plexiform type, and those in the group transplanted with AM-3-cells were similar to the follicular type. Conclusions A novel, stable animal experimental model of ameloblastoma was established using two cell lines derived from different subtypes of the tumor. This model can help clarify its pathophysiology and hasten the development of new ameloblastoma treatment strategies.Entities:
Year: 2020 PMID: 32348439 PMCID: PMC7185982 DOI: 10.1590/1678-7757-2019-0558
Source DB: PubMed Journal: J Appl Oral Sci ISSN: 1678-7757 Impact factor: 2.698
Figure 1Images of the heads of mice at each time point: 30, 60, and 90 days. (A) Negative control group: transplanted with Matrigel without cells. (B) AM-1 group: transplanted with AM-1 cells with Matrigel. (C) AM-3 group: transplanted with AM-3 cells with Matrigel. Yellow arrows indicate the tumor mass
Figure 2Histological images of H&E staining at each time point: 30, 60, and 90 days. (A) Negative control group: transplanted with Matrigel without cells. (B) AM-1 group: transplanted with AM-1 cells with Matrigel. (C) AM-3 group: transplanted with AM-3 cells with Matrigel. Arrow: Cyst formation at the tumor site in the AM-1 group. Lower panels show the areas marked by blue boxes in the upper panels. Magnification: Upper panels, 2×; Lower panels, 20×
Figure 3Histological images of the immunohistochemistry using the GFP antibody at each time point: 30, 60, and 90 days. (A) Negative control group: transplanted with Matrigel without cells. (B) AM-1 group: transplanted with AM-1 cells with Matrigel. (C) AM-3 group: transplanted with AM-3 cells with Matrigel. Magnification: 20×